© Copyright Our Wall
The “Exosome Therapeutics Market, 2022-2040”
report features an extensive study on the current market landscape, offering an
informed opinion on the likely evolution of the exosome therapies in the
treatment of various diseases.
Key Inclusions
§ General introduction to
exosomes, types of extracellular vesicles and their origin, secretion, and type
of membrane. In addition, it provides information on the development process of
exosomes and details on applications of exosomes, mechanism of different
therapies, along with the advantages, risks associated with exosome
therapeutics and the future perspectives.
§ A detailed assessment of the current market landscape of exosome therapeutics, based on several relevant parameters, such as phase of
development (clinical and preclinical), technology platform (DeliverEXTM
platform, iPSC Platform, engEx™ Platform, mTEV Platform, PEP Exosome Technologyand others), type of payload (protein, biologics, RNA, vaccine,
antisense oligonucleotide, DNA / protein and AAV capsids), target disease
indication (s) (COVID-19, acute respiratory distress syndrome, skin
regeneration, cancer and others), therapeutic area (oncological disorders,
dermatological disorders, neurological disorders, infectious diseases, rare
disorders, autoimmune disorders and respiratory disorders and others),
biological target, route of administration (intravenous, oral, subcutaneous,
intratumoral, nasal and others), type of therapy (monotherapy and combination
therapy), combination drug, line of treatment and dosing frequency. In
addition, it provides details on the companies engaged in the development of
exosome therapeutics, along with information on their year of establishment,
company size and location of headquarters.
§ Elaborate profiles of the key players engaged in the development of
exosometherapeutics, with maximum number of therapeutic programs in
their pipeline. Each profile features a brief overview of the company, its
financial information (if available), details on its product portfolio and a
section on recent developments and an informed future outlook.
§ Elaborate drug profiles of the key therapeutics . Each profile features a brief information on
product portfolio and clinical trial information including study title, study
detail, status of trial, phase of development, trial location, patient
enrollment, study start and end date.
§ A detailed analysis of completed and ongoing clinical trials of
various exosome therapeutics, based on different parameters, such as trial
status, trial registration year, type of sponsor / collaborator, study design,
and number of patients enrolled. In addition, the chapter highlights year-wise
trend of completed and recruiting trials, age group of the patients enrolled,
active industry and non-industry players and location of the trials.
§ An in-depth analysis of academic grants that have been awarded to
various research institutes for projects related to exosome therapeutics,
during the period, 2017-2022, based on several parameters, such as year of
grant awarded, amount awarded, type of funding institute center, popular NIH
departments, support period, emerging focus area, purpose of grants, grant
activity code, local recipients, type of recipient organization study section
and type of grant application. Further, the chapter also highlights the popular
recipient organizations, (in terms of number of grants and amount awarded).
§ A detailed analysis of the global events attended by the exosome therapydevelopers, based on several relevant parameters, such as year of
event, type of event platform, location of event, emerging focus areas, active
organizers (in terms of number of events), active industry and non-industry
participants, designation of participants, affiliated department of
participants, and active speakers (in terms of number of events).
§ An analysis of the partnerships that have been established in this
domain since 2017, covering instances of research agreement, licensing
agreement, manufacturing agreement, product development and commercialization
agreement, merger / acquisition, and other relevant deals.
§ A detailed analysis of the various investments made since 2017,
including grant / award, seed financing, venture capital financing, IPOs,
secondary offering, debt financing, other equity, in companies focused on the development of
exosome therapeutics.
§ An analysis of start-ups / small companies engaged in the
development of exosome therapeutics, based on parameters, such as pipeline
strength, pipeline maturity, financial support, number of investors,
partnership activity and start-up health indexing.
§ A case study highlighting the companies engaged in offering exosome
development and manufacturing services along with the information on their year
of establishment, company size, location of headquarters, types of service(s)
offered (isolation, characterization, purification, chromatography,
engineering, targeted delivery, diagnostic biomarker, and quality control),
method of isolation, method of purification, method of characterization, method
of exosome manufacturing (engineering and targeted delivery), scale of
operation (discovery / research, pre-clinical, clinical or commercialized) and
scalability (small, mid-sized or large).
§ An in-depth analysis of exosome therapeutics that failed to
progress to later stages of clinical development, based on various relevant
parameters, such as trial status of discontinuation, target disease
indication(s), route of administration and type of sponsor.
The report also features the likely distribution of the current and
forecasted opportunity across important market segments, mentioned below:
§ Type of Therapeutic
§ Allogeneic Therapy
§ AutologousTherapy
§ Target Indication(s)
§ Degenerative Meniscal Injury
§ Dystrophic Epidermolysis Bullosa
§ Fistula Perianal
§ Retinitis Pigmentosa
§ Therapeutic Area
§ Dermatological
Disorders
§ Muscoskeletal Disorders
§ Ophthalmic Diseases
§ Rectal Disorders
§ Route of Administration
§ Fistula Tract
§ Intra-articular
§ Intra-ocular
§ Geography
§ North America
§ Europe
§ Asia-Pacific and Rest
of the World
Key Questions Answered
§ Who are the leading
industry and non-industry players engaged in the development of exosome
therapies?
§ Which are the key drugs
being developed across early and late stages of development?
§ What are the key
agendas being discussed in various global events / conferences related to
exosomes?
§ What kind of
partnership models are commonly adopted by industry stakeholders?
§ Which are the leading
funding institutes / centers supporting the research related to exosome
therapies?
§ Which geographies are
the most active in conducting clinical trials related to exosome therapies?
§ How is the current and
future market opportunity, related to exosome therapies likely to be
distributed across key market segments?
To
view more details on this report, click on the link
https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html
Learn
from experts: do you know about these
emerging industry trends?
CAR-T Cell Therapies: Addressing Key
Unmet Needs Across Various Oncological Indications
Novel Cell Cytometers: Need of the
Hour
Learn from our recently published whitepaper:-
Next
Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots
Analysis
Roots Analysis is a global leader in the pharma / biotech
market research. Having worked with over 750 clients worldwide, including
Fortune 500 companies, start-ups, academia, venture capitalists and strategic
investors for more than a decade, we offer a highly analytical / data-driven
perspective to a network of over 450,000 senior industry stakeholders looking
for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
The Wall